用多巴胺基功能分子构建的纳米药物输送系统,用于有效向瘤细胞
Zhifeng Chen1, Jinglun Dai1, Nian Fu1
1School of Chemistry and Chemical Engineering GDPU, Guangdong Pharmaceutical University China wdgzyx321@163.com liuyi_papers@163.com.
RSC advances
|October 1, 2024
概括
新的纳米粒子改善了黄素在癌症治疗中的药物输送. 这些pH响应,叶酸向的纳米颗粒增强了药物溶解性和对HepG2细胞的疗效.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 药物运输 药物运输 药物运输
背景情况:
- 化疗药物往往由于水溶性差,生物分布有限以及治疗窗口狭窄而受到影响.
- 有针对性的药物输送系统对于提高治疗疗效和减少副作用至关重要.
研究的目的:
- 设计和合成新型酸敏感的希夫基分子 (PDAO和FA-DAO) 以提高药物输送.
- 开发具有双重准 (被动和主动) 能力的金载荷纳米粒子.
- 为了评估这些纳米颗粒对HepG2癌细胞的疗效.
主要方法:
- 基于多巴胺烯酸 (DAO) 的PDAO和FA-DAO分子的合成.
- 通过将DAO衍生物与水溶液中的黄素 (Cur) 混合,制备含有药物的纳米粒子.
- 在不同的pH条件下 (pH 5.0) 进行体外药物释放研究.
- 对HepG2细胞系的细胞毒性和抑制作用的评估.
主要成果:
- 含有黄素的纳米颗粒表明药物释放具有pH反应性,在pH值5.0的情况下,在24小时内释放高达70%.
- 叶酸 (FA) 在纳米颗粒上的功能化提高了主动准效率.
- 与免费药物相比,装有药物的纳米颗粒显示出对HepG2细胞的抑制作用大约增加了8倍.
结论:
- 开发的纳米颗粒显著提高了黄素的水溶性.
- 响应pH的被动向和FA介导的活跃向的结合导致了黄素对HepG2细胞的高效输送.
- 这些新型纳米颗粒代表了提高化疗疗效的有希望的战略.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


